日本語 
Royal Philips has announced that HyperVue Integrated System is now available for purchase in the United States. This new product brings imaging and heart function testing into a permanently installed setup for cardiac catheterization laboratories.
On October 30 2026 Philips announced that HyperVue Integrated System will pair DeepOCT+NIRS imaging with X1-FFR coronary physiology assessment technology. This integrated design keeps both tools linked and always ready inside an interventional suite. The setup reduces the steps that must be taken before procedures begin.
The launch shows Philips larger plan to bring imaging, heart function testing and procedure guidance tools together in care. Philips will display HyperVue Integrated System along with products at the Transcatheter Cardiovascular Therapeutics 2026 conference in San Diego, California from October 31 to November 3.
For hospitals this development solves a problem in busy catheterization laboratories. It makes advanced diagnostic tools available, without adding setup time or complexity for clinical teams.
Combining DeepOCT+NIRS Imaging With X1-FFR
HyperVue Integrated brings together two technologies that are used to assess coronary artery disease.
DeepOCT+NIRS combines optical coherence tomography and infrared spectroscopy to provide information about the structure and composition of arteries. OCT produces images of the inside of the blood vessel. NIRS helps to identify plaques that have lipid cores and to measure how much lipid is present, in the arteries.
These features allow doctors to look closely at the characteristics of arteries when they assess patients who are getting procedures.
The system also incorporates X1-FFR, an angiography-derived flow reserve (FFR) solution. FFR is used to assess the importance of narrowing in coronary arteries and to help clinicians determine whether a lesion is restricting blood flow.
According to Philips, X1-FFR uses intelligence to calculate an FFR value from a single angiographic view without needing the medication-based approach that is used in conventional invasive FFR measurement. Philips says that X1-FFR is the FDA‑cleared angiogram‑derived FFR solution that uses a single view instead of two or three.
By combining imaging with physiological assessment Philips aims to give clinicians complementary information for evaluating coronary disease and, for planning percutaneous coronary intervention (PCI).
Fixed-Room Configuration Targets Cath Lab Efficiency
A key difference between HyperVue Integrated and the mobile configuration of the HyperVue Imaging System is its permanent installation in a dedicated interventional suite.
The mobile system needs to be moved into the procedure room, powered and connected before each case. The integrated version is designed to remain installed and continuously connected, reducing these preparation requirements.
Philips has now added a touchscreen that allows clinicians to control the system at the bedside inside the sterile area. The new controller features aim to make setup easier and to give an user experience.
For hospitals that carry out coronary interventions cutting down equipment preparation steps can help clinical teams use advanced imaging in everyday work. Keeping the system ready can also make it easier to use imaging and physiology tools when clinicians need information during a procedure.
The real impact, on procedure times and operational efficiency depends on hospital workflows, staff training how complex the cases. How often the technology is used.
Philips Strengthens Its Cardiovascular Technology Portfolio
HyperVue Integrated expands Philips existing coronary guidance portfolio. This portfolio already includes ultrasound (IVUS) physiological assessment and procedural guidance technologies.
Another platform in Philips portfolio is IntraSight Plus. IntraSight Plus merges IVUS iFR/FFR physiology, co‑registration, tri‑registration and real‑time device visualization. These features help Philips clinicians at every stage of PCI from disease assessment and treatment planning to device guidance and verification of the results.
Philips broader strategy is to link information with procedural tools inside the interventional environment. Of making clinicians switch between separate systems Philips integrated platforms aim to give clinicians easier access to the needed information during complex cardiovascular procedures.
Philips will showcase HyperVue Integrated, IntraSight Plus. Other image‑guided therapy technologies at its presentation, at TCT 2026.
The launch has implications for Japan healthcare technology industry.
In Japan hospitals are under increasing pressure to improve care while dealing with workloads staffing shortages and rising healthcare costs.
Coronary artery disease remains a health concern and Japanese hospitals need tools that can support assessment and efficient treatment planning.
Imaging and physiology platforms could help Japanese medical institutions bring together sources of data into a more coordinated and effective workflow.
For hospitals the value of systems like HyperVue Integrated comes from combining imaging with assessment.
This dual perspective on disease gives clinicians information when evaluating lesions and planning interventions.
It helps clinicians make decisions in cases.
The fixed-room setup also highlights a point in healthcare technology procurement: equipment availability and how well it fits into workflows are just as important as performance.
Hospitals that look at imaging systems now need to think about how the equipment integrates into existing catheterization labs.
Hospitals must consider how much setup is required and whether staff can use the system efficiently and, without disruption.
For Japanese medical device manufacturers and healthcare technology providers, Philips’ approach shows how important it is to integrate imaging, AI-assisted analysis and procedural guidance. Companies that make systems may face growing demand for platforms that link tools together. Of offering tools providers need to build systems that work as a unified whole. This integration can improve both outcomes and operational efficiency.
Still adoption in Japan will depend on factors. These include requirements, clinical validation, reimbursement policies, hospital budgets and compatibility, with existing equipment. Just because a system launches in the US does not mean it will be available or approved in Japan. Each country has its own approval process and healthcare system needs. So while the technology may be promising its success in Japan will depend on how it meets needs and fits into the broader healthcare environment.
Business Impact on Medical Devices and Hospital Operations
The development shows how integrated medical technology is becoming more important in the equipment market. Device makers are competing not on image quality but also on how well their workflow fits the software they offer and how easily they can link different clinical functions.
For hospitals integrated platforms can give operational help. They can cut down on equipment set‑up time. Make diagnostic data easier to reach. Still buying these systems will also hinge on how they cost upfront, how much they need to be maintained how much staff training is required what clinical evidence exists and what long‑term service will be needed.
AI‑assisted physiology assessment is another topic. As hospitals look into AI tools for use technologies that help doctors, with organized diagnostic data may become more useful. Their worth will rely on proven results and proper physician oversight.
Also Read: Welby Group and TISI Partner to Expand Regional Healthcare
Outlook
Philips HyperVue Integrated System is another move toward connected environments for heart procedures. By bringing DeepOCT+NIRS imaging and X1-FFR physiology testing in a setup that is always ready the company wants to make advanced heart testing easier to use in regular catheterization lab routines.
For the healthcare technology world this new product shows the path toward combining imaging tools using artificial intelligence to help with assessments and guiding procedures. In Japan and other places how much these systems are used will rely on proof from doctors, approval, from rules makers, cost and their ability to help hospitals work better.
English